Seagen has inked a deal to develop, manufacture and commercialize an experimental immuno-oncology agent from Lava Therapeutics, a biotech firm based mostly in Utrecht, Netherlands. Seagen pays Lava $50 million upfront to completely license Lava-1223, a “bispecific T cell engager” designed to direct sure T cells to tumors through the goal EGFR on most cancers…
